ALCAM and malignant colon neoplasm: Therefore, the aim of the present study was to validate CD44 rs8193 C>T, ALCAM rs1157 G>A and LGR5 rs17109924 T>C based on our preliminary findings in a large and independent study cohort of stage II and III colon cancer patients treated with surgery plus 5-FU-based adjuvant chemotherapy or surgery alone.